Compare Inovio Pharmaceuticals Inc (INO) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PAGSEG Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while PAGSEG Inc trades at $9.37 (market cap $2.60B). The key difference: PAGSEG Inc is far larger — about 29.1× Inovio Pharmaceuticals Inc's market cap, and PAGSEG Inc pays a 11.19% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PAGS | |
|---|---|---|
Market Cap | $89.27M | $2.60B |
Sector | Health | Technology |
52-Week High | $2.87 | $12.00 |
52-Week Low | $1.05 | $7.75 |
Enterprise Value | $60.28M | $10.23B |
Dividend Yield | — | 11.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
PAGS trades at $9.29, up 2.77% today, with bearish technical signals but strong fundamentals including a P/E of 6.4 and net income margin of 10.4%. Recent earnings showed a Q1 2026 miss at $0.39 EPS versus $0.40 expected, while Q4 2025 beat expectations. The company maintains robust cash flow from operations of $7.56B in 2025 and declared a $0.26 dividend for H1 2026, payable June 1, 2026.
The stock presents a value opportunity with low valuation multiples and solid profitability, though technical weakness and mixed earnings create near-term uncertainty. Risks include Brazilian macroeconomic sensitivity and competitive pressures, but analyst consensus is strongly bullish with 62.5% buy ratings, suggesting upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
